Objective: To provide experience on the methods and costs for delivering a large-scale community pharmacist home visit service.
Setting: Independent urban community pharmacy, Buffalo, NY.
Practice Description: Mobile Pharmacy Solutions provides traditional community pharmacy walk-in service and a suite of clinically oriented services, including outbound adherence calls linked to home delivery, payment planning, medication refill synchronization, adherence packaging, and pharmacist home visits. Pharmacist daily staffing included three dispensing pharmacists, one residency-trained pharmacist, and two postgraduate year 1 community pharmacy residents.
Practice Innovation: A large-scale community pharmacy home visit service delivered over a 1-year period.
Evaluation: Pharmacist time and cost to administer the home visit service as well as home visit request sources and description of patient demographics.
Results: A total of 172 visits were conducted (137 initial, 35 follow-up). Patients who received a home visit averaged 9.8 ± 5.2 medications and 3.0 ± 1.6 chronic disease states. On average, a home visit required 2.0 ± 0.8 hours, which included travel time. The percentages of visits completed by pharmacists and residents were 60% and 40%, respectively. The amounts of time to complete a visit were similar. Average home visit cost including pharmacist time and travel was $119 ($147 for a pharmacist, $77 for a resident).
Conclusion: In this community pharmacy-based home visit service, costs are an important factor, with each pharmacist visit requiring 2 hours to complete. This experience provides a blueprint and real-world perspective for community pharmacies endeavoring to implement a home visit service and sets a foundation for future prospective trials to evaluate the impact of the service on important indicators of health and cost.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.japh.2015.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The global prevalence of interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Rheumatol Int
January 2025
School of Medicine, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia.
This study aims to review the literature and estimate the global pooled prevalence of interstitial lung disease among patients with rheumatoid arthritis (RA-ILD). The influence of risk factors like geography, socioeconomic status, smoking and DMARD use will be explored. A systematic review was performed according to the PRISMA and JBI guidelines.
View Article and Find Full Text PDFCan public education campaigns equitably counter the use of substandard and falsified (SF) medical products in African countries?
Health Policy Plan
January 2025
Department of Anthropology, Durham University, South Road, Durham, DH1 3LE, UK.
Substandard and falsified (SF) medical products are a serious health and economic concern that disproportionately impact low- and middle-income countries and marginalized groups. Public education campaigns are demand-side interventions that may reduce risk of SF exposure, but the effectiveness of such campaigns, and their likelihood of benefitting everybody, is unclear. Nationwide pilot risk communication campaigns, involving multiple media, were deployed in Ghana, Nigeria, Sierra Leone, Uganda in 2020-2021.
View Article and Find Full Text PDFModeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality.
CPT Pharmacometrics Syst Pharmacol
January 2025
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Type 2 diabetes (T2D) is a progressive metabolic disorder that could be an underlying cause of long-term complications that increase mortality. The assessment of the probability of such events could be essential for mortality risk management. This work aimed to establish a framework for risk predictions of macrovascular complications (MVC) and diabetic kidney disease (DKD) in patients with T2D, using real-world data from the Swedish National Diabetes Registry (NDR), in the presence of mortality as a competing risk.
View Article and Find Full Text PDFUtility Assessment of a Pharmacy to Dose Daptomycin Protocol: A Retrospective Cohort Study.
Ann Pharmacother
January 2025
Department of Pharmacy, Methodist Charlton Medical Center, Methodist Health System, Dallas, TX, USA.
Background: Pharmacy-to-dose (PTD) services describe an established practice where providers consult pharmacists for various medication dosing. In 2019, several institutions approved a daptomycin protocol, which allowed pharmacists to select doses based on provider-selected indications, renal function, and body mass index (BMI).
Objective: This study aims to determine the utility of a daptomycin PTD consult service.
Analgesic Overdose in Patients With Dental Pain. A Cross-Sectional Study in Two Dental Emergency Clinics.
Basic Clin Pharmacol Toxicol
February 2025
Department of Odontology, Section of Oral Biology and Immunopathology, University of Copenhagen, Copenhagen, Denmark.
Dental pain is common, and many patients use analgesics to alleviate the pain. Analgesics are readily accessible, and overdosing may lead to severe complications. This study explores the extent of analgesic overdosing in patients with dental pain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!